Skip to content

Effect of Tegileridine on Postoperative Opioid-Related Adverse Reactions in Cesarean Section

Effect of Tegileridine on Postoperative Opioid-Related Adverse Reactions in Cesarean Section

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600123056
Enrollment
Unknown
Registered
2026-04-21
Start date
2026-04-27
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-cesarean section pain

Interventions

Group T:PCIA pump 2.5mg/100ml Tegileridine
Group S:PCIA pump 100mcg/100ml sufentanil

Sponsors

Guangzhou Women and Children Medical Center Liuzhou Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Postpartum women aged over 18 years, with ASA physical status I–III, scheduled for elective cesarean section under neuraxial anesthesia

Exclusion criteria

Exclusion criteria: 1. The patient refuses to participate in the clinical study; 2. Allergy to opioids or local anesthetics; 3. Patients with chronic pain requiring chronic preoperative opioid analgesia; 4. History of dementia, psychosis, or other central nervous system disorders; 5. Patients in poor general health with a history of severe cardiovascular, respiratory, gastrointestinal, or urinary system diseases; 6. The patient has experienced any of the following within 12 months prior to surgery: myocardial infarction, severe/unstable angina, coronary artery bypass grafting, congestive heart failure, cerebrovascular accident, or pulmonary embolism; 7. Patients unable to cooperate with follow-up visits or with poor compliance; 8. Patients for whom regional infiltration anesthesia is contraindicated;

Design outcomes

Primary

MeasureTime frame
Incidence of postoperative nausea and vomiting;PCA;Supplemental analgesic;

Secondary

MeasureTime frame
NRS;QoR-15;Adverse effct;

Countries

China

Contacts

Public ContactLingyu Wang

Guangzhou Women and Children Medical Center Liuzhou Hospital

12881977@qq.com+86 188 1689 6080

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 1, 2026